Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Pfizer
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05059522CT.gov Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | — | Active Not Recruiting | — | — | — |
NCT04601402CT.gov GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | — | Completed | — | — | — |
NCT04260802CT.gov A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | — | Terminated | — | — | — |
NCT04571632CT.gov Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors | — | Unknown | — | — | — |
NCT03861403CT.gov A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03815643CT.gov Avelumab Program Rollover Study | — | Active Not Recruiting | — | — | — |
NCT03724890CT.gov Study of Avelumab-M3814 Combinations | — | Completed | — | — | — |
NCT03270176CT.gov A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy | — | Completed | — | — | — |
NCT03252938CT.gov Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03491345CT.gov K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor | — | Unknown | — | — | — |
Show 4 more trialsShow fewer
NCT02630368CT.gov A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) | — | Unknown | — | — | — |
NCT02222922CT.gov A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01943461CT.gov Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN) | — | Completed | — | — | — |
NCT01772004CT.gov Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avelumab (this asset) | Pfizer | P3 | CCC · 55 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Avelumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 58 |
| Urothelial Carcinoma | — | P3 | B · 58 |
| Bladder Transitional Cell Carcinoma | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Avelumab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avelumab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →